Clinical Trial Update: Optimal Neo-adjuvant Combination Scheme of Ipilimumab and Nivolumab [Phase 2]

View source ↗

Summary

Phase 2 trial update evaluating optimal neo-adjuvant combination therapy with ipilimumab and nivolumab for malignant melanoma stage III.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Malignant Melanoma

Drugs mentioned

• ipilimumab (ipilimumab)
• nivolumab (nivolumab)

Snippet

Sponsor: The Netherlands Cancer Institute | Conditions: Malignant Melanoma Stage III | Phase 2 | Status: UNKNOWN